Original language | English (US) |
---|---|
Pages (from-to) | 1445-1449 |
Number of pages | 5 |
Journal | Neurology and Therapy |
Volume | 11 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2022 |
Keywords
- Aquaporin-4 immunoglobulin G-positive
- Bayesian network meta-analysis
- Eculizumab
- Inebilizumab
- Matching-adjusted indirect comparison
- Neuromyelitis optica spectrum disorder
- Randomized controlled trial
- Satralizumab
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology and Therapy, Vol. 11, No. 3, 09.2022, p. 1445-1449.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - A Response to
T2 - Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
AU - Wingerchuk, Dean M.
AU - Zhang, Ina
AU - Kielhorn, Adrian
AU - Royston, Minying
AU - Levy, Michael
AU - Fujihara, Kazuo
AU - Nakashima, Ichiro
AU - Tanvir, Imran
AU - Paul, Friedemann
AU - Pittock, Sean J.
N1 - Funding Information: Editorial support was provided by Steven F. Merkel, PhD, of Oxford PharmaGenesis, Inc., Newtown, PA, and was funded by Alexion, AstraZeneca Rare Disease, Boston, MA, USA. Funding Information: We would like to thank Dr. Jeroen Jansen of PRECISIONheor for his insights related to potential bias in network meta-analyses and indirect comparisons relevant to drafting this response. Financial support for development of this letter was provided by Alexion, AstraZeneca Rare Disease, Boston, MA, USA. No funding was received for the publication of this letter. Editorial support was provided by Steven F. Merkel, PhD, of Oxford PharmaGenesis, Inc., Newtown, PA, and was funded by Alexion, AstraZeneca Rare Disease, Boston, MA, USA. Conception, preparation, and critical review of this letter was provided by all authors. The study sponsor reviewed the letter, and all authors read and approved the final version. Imran Tanvir is a former employee and stockholder of Alexion, AstraZeneca Rare Disease; he is currently an employee of Genentech. Adrian Kielhorn is an employee and stockholder of Alexion, AstraZeneca Rare Disease. Minying Royston is a former employee and stockholder of Alexion, AstraZeneca Rare Disease; she is currently an employee of Dicerna Pharmaceuticals, Inc. Michael Levy is an employee of Massachusetts General Hospital and has received consulting fees and grants from Alexion, AstraZeneca Rare Disease, Viela Bio, and Genentech relevant to the manufacturers of the three drugs mentioned in this letter. Ichiro Nakashima is an employee of Tohoku Medical and Pharmaceutical University and has received speech honoraria and consulting fees from Alexion, AstraZeneca Rare Disease and Chugai Pharmaceutical. Kazuo Fujihara received honoraria for lectures and presentations from Alexion, AstraZeneca Rare Disease, Roche/Chugai, and Viela Bio, and served on their advisory boards. Sean J. Pittock and his institution have received honoraria and travel expenses for attending NMOSD advisory board meetings (MedImmune, Alexion, AstraZeneca Rare Disease); consulting fees (Alexion, AstraZeneca Rare Disease, Euroimmun, Grifols, MedImmune); grant/research support (Alexion, AstraZeneca Rare Disease, the Autoimmune Encephalitis Alliance, Euroimmun, Grifols, MedImmune); and other fees from the National Institutes of Health and the Guthy-Jackson Charitable Foundation. Dean M. Wingerchuk is an employee of the Mayo Clinic and participated on a data safety monitoring or advisory board for Roche, Viela Bio, Genentech, Biogen, Reistone, TG Therapeutics, Celgene, and Novartis, with fees paid directly to himself; and for Alexion, AstraZeneca Rare Disease with fees paid to his institution. He received grants for clinical trials through Alexion, AstraZeneca Rare Disease and TerumoBCT paid directly to his institution and was personally paid consulting fees by Mitsubishi Tanabe. Ina Zhang is an employee of PRECISIONheor, who received funding from Alexion, AstraZeneca Rare Disease. Friedemann Paul is an employee of Charité-Universitätsmedizin Berlin and has received honoraria for lectures and research support from Alexion, AstraZeneca Rare Disease. He has received grants for research support (recipient Charité) from German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, the Guthy-Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel, and Almirall. He has received personal payment and travel expenses for lectures, presentations, and speakers’ bureaus from the Guthy-Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe, and Celgene. He has participated on an advisory board for Celgene, Roche, UCB, and Merck. He has offered unpaid Neurol Ther support as an Academic Editor for PLOS ONE and as Associate Editor for Neurology : Neuroimmunology & Neuroinflammation. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
PY - 2022/9
Y1 - 2022/9
KW - Aquaporin-4 immunoglobulin G-positive
KW - Bayesian network meta-analysis
KW - Eculizumab
KW - Inebilizumab
KW - Matching-adjusted indirect comparison
KW - Neuromyelitis optica spectrum disorder
KW - Randomized controlled trial
KW - Satralizumab
UR - http://www.scopus.com/inward/record.url?scp=85133264634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133264634&partnerID=8YFLogxK
U2 - 10.1007/s40120-022-00378-0
DO - 10.1007/s40120-022-00378-0
M3 - Letter
AN - SCOPUS:85133264634
SN - 2193-8253
VL - 11
SP - 1445
EP - 1449
JO - Neurology and Therapy
JF - Neurology and Therapy
IS - 3
ER -